155 320

Cited 0 times in

Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?

DC Field Value Language
dc.contributor.author김준원-
dc.date.accessioned2021-12-28T17:41:33Z-
dc.date.available2021-12-28T17:41:33Z-
dc.date.issued2021-09-
dc.identifier.issn2234-1900-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187225-
dc.description.abstractPurpose: Studies on de-escalation in radiation therapy (RT) for human papillomavirus-related (HPV(+)) oropharyngeal cancer (OPC) are currently ongoing. This study investigated the current practice regarding the radiation dose and field in the treatment of HPV(+) OPC. Materials and methods: The Korean Society for Head and Neck Oncology conducted a questionnaire on the primary treatment policy. Among them, for HPV(+) OPC scenarios, radiation oncologists were questioned regarding the field and dose of RT. Results: Forty-two radiation oncologists responded to the survey. In definitive concurrent chemoradiotherapy (CCRT) treatment for stage T2N1M0 OPC, most respondents prescribed a dose of >60 Gy to the primary tonsil and involved ipsilateral lymph nodes. However, eight of the respondents prescribed a relatively low dose of ≤54 Gy. For stage T2N1M0 OPC, postoperative adjuvant RT was prescribed by eight and nine respondents with a lower dose of ≤50 Gy for the ipsilateral tonsil and involved neck, respectively. In definitive CCRT in complete remission after induction chemotherapy for initial stage T2N3M0 OPC, de-escalation of the tonsil and involved neck were performed by eight and seven respondents, respectively. Regarding whether de-escalation is applied in radiotherapy for HPV(+) OPC, 27 (64.3%) did not do it at present, and 15 (35.7%) were doing or considering it. Conclusion: The field and dose of prescribed treatment varied between institutions in Korea. Among them, dose de-escalation of RT in HPV(+) OPC was observed in approximately 20% of the respondents. Consensus guidelines will be set in the near future after the completion of ongoing prospective trials.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Society for Therapeutic Radiology and Oncology-
dc.relation.isPartOfRADIATION ONCOLOGY JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSurvey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorKyu Hye Choi-
dc.contributor.googleauthorJin Ho Song-
dc.contributor.googleauthorYeon-Sil Kim-
dc.contributor.googleauthorSung Ho Moon-
dc.contributor.googleauthorJeongshim Lee-
dc.contributor.googleauthorYoung-Taek Oh-
dc.contributor.googleauthorDongryul Oh-
dc.contributor.googleauthorJin Ho Kim-
dc.contributor.googleauthorJun Won Kim-
dc.identifier.doi10.3857/roj.2021.00556-
dc.contributor.localIdA00958-
dc.relation.journalcodeJ02592-
dc.identifier.eissn2234-3164-
dc.identifier.pmid34610656-
dc.subject.keywordDe-escalation-
dc.subject.keywordDose and Field-
dc.subject.keywordHuman papillomavirus-
dc.subject.keywordOropharyngeal cancer-
dc.subject.keywordRadiotherapy-
dc.contributor.alternativeNameKim, Jun Won-
dc.contributor.affiliatedAuthor김준원-
dc.citation.volume39-
dc.citation.number3-
dc.citation.startPage174-
dc.citation.endPage183-
dc.identifier.bibliographicCitationRADIATION ONCOLOGY JOURNAL, Vol.39(3) : 174-183, 2021-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.